Navigation Links
Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009
Date:3/31/2009

BELGRADE, SERBIA, March 31 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com - The "Best Technological Innovation Award" is a most coveted, prestigious award, and is announced annually by the Serbian Ministry of Science and Technological Development. Submitted with the award application, HTDS included extremely encouraging results from the preliminary trial of their Ribavirin product, confirming its combative effective against glial scarring.

HTDS Chief Scientist, Dr. Sanja Pekovic was elected as an expert to represent Serbia in the COST (European Cooperation In The Field of Scientific And Technical Research) Action B30: Neural Regeneration and Plasticity. Meetings are scheduled twice a year.

Recently, HTDS - IBISS GROUP competed for the European Collaborative Project (FP7). Dr. Pekovic said "We are delighted to have successfully passed the first level of selection. HTDS is looking forward to another great year." Final results will be released sometime in 2009.

The company will provide further details as they become available.

Safe Harbor

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Australian clinical trials threatened: Jobs and patient access to new treatments at stake
2. US Market for Minimally Invasive Treatment of Varicose Veins to Rise to More than $215 Million by 2013
3. Prostate Cancer Patients in US and Europe Receive Treatments Using Enhanced Seed Prostate Brachytherapy Software
4. Ear Health News: Natural Treatments to Ease Tinnitus Intensity
5. Arthritis Treatments and Joint Pain Relief Ideas Featured on Newly Launched Arthritis Today Web Site
6. New Device Treats Common Heart Rhythm Disorder
7. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
8. Microsurgery May Cut Swelling After Breast Cancer Treatment
9. Treatment Target for Herpes Pinpointed
10. Plastic Surgeon Allan Parungao, MD, FACS, Announces Clinical Trial of Juvderm Technique to Treat Root Cause of Midface Sagging, without Surgery
11. Individualized stroke treatment available for patients, though underutilized
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 ... ... provides an agile ecosystem and domain expertise for sponsors and CROs to ... and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... 2017 , ... A stressful work environment can hurt the physical and emotional ... performance in the workplace. The goal of Clearview Resolution Services has always been to ... Clearview Resolution Services will be shutting down the office early on Fridays. The Clearview ...
(Date:4/25/2017)... CO (PRWEB) , ... April 25, 2017 , ... ... and Liberty attempts to compare student test score performance for the 2015-16 school ... of the state’s voucher programs. Though it highlights important patterns in student test ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: